IL1B and benign prostatic hyperplasia: In a multicentered pilot study, Vela Navarrete et al., reported that a 3-month treatment with 160 mg SP extract (Permixon®) could significantly reduce the IPSS score alongside the inflammatory parameters IL-1β and TNF-α in prostate tissues of BPH patients [30].